ATRY Stock Overview
Provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Atrys Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.13 |
| 52 Week High | €4.48 |
| 52 Week Low | €2.77 |
| Beta | 0.54 |
| 1 Month Change | -3.69% |
| 3 Month Change | 1.29% |
| 1 Year Change | -16.53% |
| 3 Year Change | -69.31% |
| 5 Year Change | -39.22% |
| Change since IPO | 95.63% |
Recent News & Updates
Recent updates
Atrys Health, S.A.'s (BME:ATRY) 38% Share Price Surge Not Quite Adding Up
May 25
Is Atrys Health, S.A. (BME:ATRY) Trading At A 44% Discount?
Sep 09The Returns At Atrys Health (BME:ATRY) Aren't Growing
Jun 27Returns On Capital Are Showing Encouraging Signs At Atrys Health (BME:ATRY)
Nov 26Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger
Aug 12Did You Miss Atrys Health's (BME:ATRY) Whopping 387% Share Price Gain?
Feb 02
Atrys Health, S.A. (BME:ATRY) Shares Could Be 33% Above Their Intrinsic Value Estimate
Dec 11Shareholder Returns
| ATRY | ES Healthcare | ES Market | |
|---|---|---|---|
| 7D | 2.0% | -1.1% | -1.2% |
| 1Y | -16.5% | 4.0% | 12.3% |
Return vs Industry: ATRY underperformed the Spanish Healthcare industry which returned 4% over the past year.
Return vs Market: ATRY underperformed the Spanish Market which returned 12.3% over the past year.
Price Volatility
| ATRY volatility | |
|---|---|
| ATRY Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in ES Market | 6.0% |
| 10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: ATRY has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: ATRY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,084 | Isabel Lozano Fernandez | www.atryshealth.com |
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests.
Atrys Health, S.A. Fundamentals Summary
| ATRY fundamental statistics | |
|---|---|
| Market cap | €237.68m |
| Earnings (TTM) | -€31.51m |
| Revenue (TTM) | €211.11m |
1.1x
P/S Ratio-7.5x
P/E RatioIs ATRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRY income statement (TTM) | |
|---|---|
| Revenue | €211.11m |
| Cost of Revenue | €155.67m |
| Gross Profit | €55.44m |
| Other Expenses | €86.95m |
| Earnings | -€31.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 26.26% |
| Net Profit Margin | -14.93% |
| Debt/Equity Ratio | 80.9% |
How did ATRY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 21:40 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atrys Health, S.A. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Victor Peiro Pérez | GVC Gaesco Valores |
| Joaquin Garcia-Quiros | JB Capital Markets |